|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Property & equipment | ||||||||||||||||||||
| Patents (net of $58,918 amortization and $556,120 impairment) | ||||||||||||||||||||
| Intangible assets | ||||||||||||||||||||
| Deferred tax asset | ||||||||||||||||||||
| Right-of-use-asset | ||||||||||||||||||||
| Total Long-Term Assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||||
| Accounts payable & accrued expenses | ||||||||||||||||||||
| Earnout payable | ||||||||||||||||||||
| Income tax payable | ||||||||||||||||||||
| Right-of-use-liability | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Long-Term Liabilities: | ||||||||||||||||||||
| Deferred tax liability | ||||||||||||||||||||
| Right-of-use-liability | ||||||||||||||||||||
| Total Long-Term Liabilities | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| Preferred Stock Series B $0.10 par value per share; 1,000,000 shares authorized 130,000 shares issued and outstanding | ||||||||||||||||||||
| Total preferred Stock Series B $0.10 par value per share; 1,000,000 shares authorized 130,000 shares issued and outstanding | ||||||||||||||||||||
| Common Stock $0.001 par value per share; 3,000,000,000 shares authorized 2,388,516 shares issued and outstanding at June 30, 2026 and 490,595 shares issued and outstanding at December 31, 2025 | ||||||||||||||||||||
| Capital paid in excess of par value | ||||||||||||||||||||
| Accumulated comprehensive income | ||||||||||||||||||||
| Accumulated (Deficit) | ||||||||||||||||||||
| TOTAL SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||
Loading...
